Trial site
Specialty Clinical Research of St. Louis
St Louis, Missouri 63141, United StatesNot linked to an institution yet
- 10running trials
- 2closed trials
The trials here
What the 12 trials at this site are about, from their registry records.
- Phase
- Phase 35 trials
- Phase 23 trials
- Phase 1/22 trials
- Status
- Active, not recruiting5 trials
- Recruiting5 trials
- Completed2 trials
- Lead sponsor
- CG Oncology, Inc.3 trials
- Janssen Research & Development, LLC3 trials
- Sumitomo Pharma America, Inc.2 trials
- Dendreon1 trial
- Ferring Pharmaceuticals1 trial
- and 2 more
Running trials
Recruiting
A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States
NCT07309445· Janssen Research & Development, LLC· Source
Contact: Eliza M. Raymundo, MD, DMCC, FPUA, FPCS
Recruiting
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
NCT06995677· Phase 2· Tyra Biosciences, Inc· Source
Contact: Gina Risdall
Recruiting
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
NCT06510374· Phase 3· Ferring Pharmaceuticals· Source
Contact: Ferring Pharmaceuticals
Recruiting
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
NCT06567743· Phase 2· CG Oncology, Inc.· Source
Contact: Gregory Auffenberg, MD
Active, not recruiting
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
NCT06211764· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
NCT06111235· Phase 3· CG Oncology, Inc.· Source
Recruiting
Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
NCT06134232· Phase 2· Dendreon· Source
Contact: Brittany Minor
Active, not recruiting
Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
NCT05316155· Phase 1/2· Janssen Research & Development, LLC· Source
Active, not recruiting
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
NCT04452591· Phase 3· CG Oncology, Inc.· Source
Active, not recruiting
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
NCT02138734· Phase 1/2· ImmunityBio, Inc.· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error